Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain

blonca9
Jan 29
1 min read

CEO Jan Thirkettle describes the company's approach to upregulating genes for neurodegenerative diseases and how Harness is out front in targeting FAN1 for Huntington's.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight